16209 AML Risk Stratification: Influence of emerging cytogenetics and molecular markers on treatment decisions 4-5pm (CDT) - September 29, 2016

Minneapolis, MN US
September 29, 2016

Emerging molecular genetic and cytogenetic alterations are changing the landscape of treatment decision-making in AML. Using an interactive, case study-based format, speakers will discuss the prognostic importance of cytogenetic and molecular marker testing and how results are used to develop risk-adapted treatment choices to achieve optimal outcomes for patients. Speakers will also discuss recommended standards of care for patients with intermediate- and high-risk AML.

 

ACCME Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and National Marrow Donor Program. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

 

AMA Credit Designation Statement:

The Medical College of Wisconsin designates this Enduring Material for a maximum of 1 AMA PRA Category 1 Credit(s) ™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1 hours of participation for continuing education for allied health professionals.  

 

Questions?

If you have any questions regarding this activity, contact Nicole Heino, continuing education manager, Education and Training, NMDP/Be The Match at (800) 526-7809 ext. 4811, or email nheino@nmdp.org.

Target Audience

Hematologist
Oncologists
Nurse Practitioners
Physician Assistants
Allied Health Professionals 

Learning Objectives

At the conclusion of this activity, I will be able to:

  1. Describe which cytogenetic and molecular marker testing should be completed for patients newly diagnosed with AML
  2. Cite the latest research that revises categorization for intermediate- or high-risk disease
  3. Apply cytogenetic and molecular marker risk stratification to inform prognosis and guide therapeutic options

 

Additional information

Contact

Name: 
Nicole Heino
Phone Number: 
+1 (763) 406-4811
Email: 
nheino@nmdp.org
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
09/29/2016
Course expires: 
12/30/2016
Event starts: 
09/29/2016 - 4:00pm CDT
Event ends: 
09/29/2016 - 5:00pm CDT
Cost:
$0.00
Part of: 
National Marrow Donor Program Webinar Series
Add to calendar: 
National Marrow Donor Program/Be The Match
500 N 5th Street
Minneapolis, MN 55401-1206
United States
Planning Committee:
Laura Michaelis, MD
Linda Burns, MD
Balkrishna Jahagirdar, MD
Sergio Giralt, MD
Navneet Majhail, MD, MS
Elizabeth Murphy, EdD, RN
Darlene Haven
Nicole Heino
Ellyce Hayes
Sara Roedl, PhD
Jackie Foster, MPH, RN, OCN
Ellen Denzen, MS
Heather Moore
Christa Meyer
 
 
Speakers
Clara D. Bloomfield, M.D. (moderator)
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital
and Richard J. Solove Research Institute
 
Aaron Gerds, M.D.
Cleveland Clinic
Taussig Cancer Institute
 
Jessica Altman, M.D.
Northwestern University Feinberg School of Medicine
Robert H. Lurie Cancer Center
 
 
All persons in control of content has no relevant financial relationships to disclose with the exception of the following persons;
 
NameCompanyRole
Sergio Giralt, MDCelgene, Sanofi, Jazz, Takeda, AmgenResearch, Advisory Board
Laura Michaelis, MDIncyte, Celgene, PfizerConsultant, Stock Owner
Navneet Majhail, MDAnthem Inc., SanofiConsultant, Speaker
Jackie Foster, MPH, RNPfizerStock Owner
Aaron Gerds, MDIncyte, CTI BiopharmaAdvisory Board
Jessica Altman, MDSyros, BMS, Astellas, Janssen, ASH, NCCNAdvisory Board
 

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.